FDA announces partnership with NIH for scientific research to promote FDA's tobacco regulatory agenda

[Bill Godshall]

After lying about the scientific evidence by falsely (and still) claiming "To date, no tobacco products have been scientifically proven to reduce risk of tobacco-related disease, improve safety or cause less harm than other tobacco products," at http://www.fda.gov/TobaccoProducts/ResourcesforYou/ucm255658.htm,
the FDA has announced a partnership with NIH to fund scientic research to advance FDA's regulatory agenda.
RFA-DA-13-003: Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (P50)


Research Priorities of the FDA Center for Tobacco Products
Science will inform FDA in regulation of the manufacture, marketing, and distribution of tobacco products in order to reduce the public health toll from tobacco product use in the United States. The research supported by this initiative will provide scientific evidence within the following seven FDA CTP research interest areas:

• Diversity of Tobacco Products - understanding the constituents, components, ingredients, additives, and design features; use behaviors; perceptions, attitudes and beliefs of conventional and new and emerging tobacco products
• Reducing Addiction - understanding dependence in relation to nicotine level; how reductions in nicotine affect use behaviors; other constituents and components beyond nicotine that affect addiction of combustible and non-combustible tobacco products
• Reducing Toxicity and Carcinogenicity - understanding how reductions in toxicity of tobacco products affect use behaviors and perceptions; what level of reduction in harmful and potentially harmful constituents result in decreased disease risk; what assays best compare toxicity between different tobacco products
• Adverse Health Consequences - understanding health risks of multiple tobacco types; what biomarkers of disease risk can be associated with measures of tobacco exposure; what novel biological and physiological markers are predictive of tobacco-related adverse health outcomes
• Communications - understanding how to effectively convey information regarding risks associated with tobacco product use and FDA's regulatory authority over tobacco products
• Marketing of Tobacco Products - understanding the impact of tobacco product marketing on use behaviors, perception, attitudes and beliefs
• Economics and Policies - estimating the economic impact of FDA regulatory actions; understanding the impact of FDA regulatory actions on tobacco use and on overall morbidity and mortality

 

[NorthOfAtlanta]

I can bet on one thing they won't do, survey ecig users to find out how many of us have quit long term cigarette habits after trying everything that they recommend several times. Also can't see them just accepting all of the Swedish studies that have been done on sunus users over the last thirty years as they would save way to much money and won't be able to expand their power base by hiring more people to reinvent the wheel.

 

[VapApe]

If the FDA reinvented the wheel it would have four equal sides.